Literature DB >> 15331445

Tumor suppressor function of Bruton tyrosine kinase is independent of its catalytic activity.

Sabine Middendorp1, A J Esther Zijlstra, Rogier Kersseboom, Gemma M Dingjan, Hassan Jumaa, Rudolf W Hendriks.   

Abstract

During B-cell development in the mouse, Bruton tyrosine kinase (Btk) and the adaptor protein SLP-65 (Src homology 2 [SH2] domain-containing leukocyte protein of 65 kDa) limit the expansion and promote the differentiation of pre-B cells. Btk is thought to mainly function by phosphorylating phospholipase Cgamma2, which is brought into close proximity of Btk by SLP-65. However, this model was recently challenged by the identification of a role for Btk as a tumor suppressor in the absence of SLP-65 and by the finding that Btk function is partially independent of its kinase activity. To investigate if enzymatic activity is critical for the tumor suppressor function of Btk, we crossed transgenic mice expressing the kinase-inactive K430R-Btk mutant onto a Btk/SLP-65 double-deficient background. We found that K430R-Btk expression rescued the severe developmental arrest at the pre-B-cell stage in Btk/SLP-65 double-deficient mice. Moreover, K430R-Btk could functionally replace wild-type Btk as a tumor suppressor in SLP-65- mice: at 6 months of age, the observed pre-B-cell lymphoma frequencies were approximately 15% for SLP-65- mice, 44% for Btk/SLP-65-deficient mice, and 14% for K430R-Btk transgenic mice on the Btk/SLP-65-deficient background. Therefore, we conclude that Btk exerts its tumor suppressor function in pre-B cells as an adaptor protein, independent of its catalytic activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331445     DOI: 10.1182/blood-2004-07-2708

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

Review 1.  Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.

Authors:  Markus Müschen
Journal:  Blood       Date:  2015-04-15       Impact factor: 22.113

Review 2.  Gastric adenocarcinoma in the context of X-linked agammaglobulinemia: case report and review of the literature.

Authors:  Aidé Tamara Staines Boone; María Guadalupe Torres Martínez; Gabriela López Herrera; Julia O de Leija Portilla; Sara Elva Espinosa Padilla; Francisco J Espinosa Rosales; Saúl Oswaldo Lugo Reyes
Journal:  J Clin Immunol       Date:  2013-12-12       Impact factor: 8.317

Review 3.  The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.

Authors:  Leslie J Crofford; Lindsay E Nyhoff; Jonathan H Sheehan; Peggy L Kendall
Journal:  Expert Rev Clin Immunol       Date:  2016-03-04       Impact factor: 4.473

4.  Kinomics platform using GBM tissue identifies BTK as being associated with higher patient survival.

Authors:  Sofian Al Shboul; Olimpia E Curran; Javier A Alfaro; Fiona Lickiss; Erisa Nita; Jacek Kowalski; Faris Naji; Rudolf Nenutil; Kathryn L Ball; Radovan Krejcir; Borivoj Vojtesek; Ted R Hupp; Paul M Brennan
Journal:  Life Sci Alliance       Date:  2021-10-13

5.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

6.  Noncatalytic Bruton's tyrosine kinase activates PLCγ2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells.

Authors:  Martin Wist; Laura Meier; Orit Gutman; Jennifer Haas; Sascha Endres; Yuan Zhou; Reinhild Rösler; Sebastian Wiese; Stephan Stilgenbauer; Elias Hobeika; Yoav I Henis; Peter Gierschik; Claudia Walliser
Journal:  J Biol Chem       Date:  2020-03-17       Impact factor: 5.157

7.  Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages.

Authors:  Lindsay E Nyhoff; Emily S Clark; Bridgette L Barron; Rachel H Bonami; Wasif N Khan; Peggy L Kendall
Journal:  J Immunol       Date:  2018-02-26       Impact factor: 5.422

8.  Differential sensitivity to Itk kinase signals for T helper 2 cytokine production and chemokine-mediated migration.

Authors:  Nisebita Sahu; Cynthia Mueller; Angela Fischer; Avery August
Journal:  J Immunol       Date:  2008-03-15       Impact factor: 5.422

9.  Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells.

Authors:  Niklas Feldhahn; Florian Klein; Jana L Mooster; Paul Hadweh; Mieke Sprangers; Maria Wartenberg; Mohamed M Bekhite; Wolf-Karsten Hofmann; Sebastian Herzog; Hassan Jumaa; Janet D Rowley; Markus Müschen
Journal:  J Exp Med       Date:  2005-06-06       Impact factor: 14.307

Review 10.  Targeting Bruton's tyrosine kinase in B cell malignancies.

Authors:  Rudi W Hendriks; Saravanan Yuvaraj; Laurens P Kil
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.